---
title: "Jubilant Pharmova Ltd (JUBLPHARMA) — Share Price, Financials & Analysis"
symbol: "JUBLPHARMA"
company: "Jubilant Pharmova Ltd"
canonical: "https://tapetide.com/stocks/JUBLPHARMA"
isin: "INE700A01033"
nse_symbol: "JUBLPHARMA"
bse_code: "530019"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 16124.83
generated_at: "2026-09-13T19:50:50.530Z"
---

# Jubilant Pharmova Ltd (JUBLPHARMA)

Canonical page: https://tapetide.com/stocks/JUBLPHARMA

## Company

- **NSE Symbol:** JUBLPHARMA
- **BSE Code:** 530019
- **ISIN:** INE700A01033
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2003-06-16
- **CEO:** Mr. Priyavrat Bhartia MBA
- **Employees:** 5547
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** jubl.com

## About

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

## Latest Price

- **Price:** ₹1025.2
- **Change:** -0.45 (-0.04%)
- **Open:** ₹1020
- **Day High:** ₹1034.15
- **Day Low:** ₹1006.3
- **Previous Close:** ₹1025.65
- **Volume:** 230939
- **As Of:** 2026-09-11T10:25:56+00:00

## Key Fundamentals

Observed at 2026-09-11T04:48:41.666053Z.

- **Market Cap:** ₹16124.83 Cr
- **Classification:** Smallcap
- **P/E (reported):** 46.5
- **P/E (TTM):** 46.37
- **EPS (TTM):** ₹22.11
- **EPS (reported):** ₹14.96
- **Book Value:** ₹445.26
- **Price to Book:** 2.3
- **Dividend Yield:** 0.49%
- **ROE:** 5.6%
- **ROCE:** 6.36%
- **Debt to Equity:** 0.51
- **Revenue (yearly):** ₹8345.6 Cr
- **Net Income:** ₹397.5 Cr
- **EBITDA:** ₹1325.8 Cr
- **52-Week High:** ₹1184.8
- **52-Week Low:** ₹786.05
- **RSI (14):** 74.26

## Tapetide Score

- **Score:** 46 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Fair · Momentum: Falling
- **Percentile:** 31.9 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 15.11 | 9% |
| growth | 48.74 | 9% |
| momentum | 36.07 | 12% |
| ownership | 62.4 | 24% |
| quality | 35.59 | 22% |
| valuation | 57.26 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has been maintaining a healthy dividend payout of 43.9%
- Company's working capital requirements have reduced from 28.6 days to 13.4 days

### Weaknesses

- The company has delivered a poor sales growth of 6.31% over past five years.
- Company has a low return on equity of 4.91% over last 3 years.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 14.43% | 26.3% | 46.48% |
| ebitda margin growth | -21.69% | -5.86% | 10.96% | -16.41% |
| net income growth | -52.72% | -52.47% | 47% | -13% |
| revenue growth | -2.39% | 14.46% | 10% | 6% |
| roce | -39.53% | -44.84% | 38.86% | 6.8% |
| roe | -52.72% | -58.24% | 6.78% | -27.93% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1680 | 1677 | 1759 | 1732 | 1752 | 1822 | 1929 | 1901 | 1966 | 2122 | 2290 | 2229 |
| Expenses | 1438 | 1459 | 1487 | 1480 | 1463 | 1535 | 1584 | 1611 | 1625 | 1833 | 1951 | 1981 |
| Operating Profit | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 |
| OPM % | 14 | 13 | 15 | 15 | 17 | 16 | 18 | 15 | 17 | 14 | 15 | 11 |
| Other Income | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 |
| Interest | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 56 | 54 |
| Depreciation | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 |
| Profit before tax | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 | 190 | 93 | 176 | 86 |
| Tax % | 37 | 34 | 15 | 4 | 29 | 23 | 27 | 34 | 37 | 40 | 32 | 35 |
| Net Profit | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 | 120 | 56 | 119 | 56 |
| EPS in Rs | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 | 3.51 | 7.5 | 3.55 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 7518 | 9111 | 5976 | 6099 | 6130 | 6282 | 6703 | 7234 | 8280 | 8608 |
| Expenses | 5995 | 7367 | 4428 | 4695 | 4980 | 5503 | 5802 | 6061 | 7020 | 7390 |
| Operating Profit | 1522 | 1744 | 1548 | 1403 | 1150 | 779 | 901 | 1173 | 1260 | 1218 |
| OPM % | 20 | 19 | 26 | 23 | 19 | 12 | 13 | 16 | 15 | 14 |
| Other Income | 36 | -249 | 225 | 263 | 8 | -9 | -76 | 416 | 7 | 15 |
| Interest | 284 | 220 | 200 | 184 | 145 | 188 | 272 | 240 | 212 | 217 |
| Depreciation | 415 | 371 | 340 | 349 | 382 | 554 | 382 | 369 | 440 | 470 |
| Profit before tax | 859 | 904 | 1233 | 1133 | 630 | 28 | 170 | 981 | 614 | 546 |
| Tax % | 26 | 36 | 27 | 26 | 34 | 333 | 57 | 15 | 35 | — |
| Net Profit | 634 | 577 | 898 | 836 | 413 | -65 | 73 | 836 | 398 | 351 |
| EPS in Rs | 40.35 | 36.06 | 56.39 | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 25.02 | 22.11 |
| Dividend Payout % | 7 | 12 | 9 | 10 | 19 | -130 | 102 | 9 | 20 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 3420 | 4071 | 4793 | 5588 | 4726 | 5303 | 5383 | 5418 | 6239 | 7077 |
| Borrowings | 4045 | 3469 | 4840 | 4808 | 2830 | 3192 | 3677 | 3664 | 2731 | 3615 |
| Other Liabilities | 1417 | 1902 | 1670 | 1898 | 1192 | 1319 | 1853 | 2240 | 3598 | 4564 |
| Total Liabilities | 8899 | 9457 | 11319 | 12310 | 8763 | 9830 | 10929 | 11338 | 12584 | 15272 |
| Fixed Assets | 5107 | 5401 | 5648 | 6340 | 4609 | 4871 | 5183 | 5091 | 5176 | 6966 |
| CWIP | 684 | 671 | 901 | 768 | 897 | 1090 | 1562 | 2103 | 3630 | 4040 |
| Investments | 103 | 124 | 115 | 69 | 241 | 239 | 256 | 42 | 44 | 61 |
| Other Assets | 3006 | 3262 | 4654 | 5133 | 3017 | 3631 | 3928 | 4101 | 3735 | 4205 |
| Total Assets | 8899 | 9457 | 11319 | 12310 | 8763 | 9830 | 10929 | 11338 | 12584 | 15272 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 1268 | 1303 | 1122 | 1543 | 1784 | 838 | 661 | 971 | 1072 | 1227 |
| Cash from Investing Activity | -465 | -614 | -1018 | -267 | -727 | -323 | -474 | -596 | 512 | -1143 |
| Cash from Financing Activity | -686 | -901 | 657 | -1050 | -1709 | -33 | -157 | -432 | -1453 | 95 |
| Net Cash Flow | 117 | -212 | 761 | 225 | -652 | 482 | 30 | -58 | 132 | 179 |
| Free Cash Flow | 806 | 819 | 473 | 975 | 1270 | 241 | -135 | 83 | -38 | -120 |
| CFO/OP | 104 | 103 | 84 | 116 | 155 | 90 | 111 | 131 | 112 | 114 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 63 | 55 | 51 | 79 | 49 | 55 | 56 | 50 | 45 | 47 |
| Inventory Days | 223 | 177 | 147 | 463 | 268 | 308 | 268 | 220 | 178 | 170 |
| Days Payable | 137 | 145 | 106 | 273 | 124 | 139 | 160 | 146 | 158 | 170 |
| Cash Conversion Cycle | 149 | 87 | 92 | 268 | 194 | 224 | 165 | 124 | 65 | 47 |
| Working Capital Days | 50 | 45 | 45 | 62 | 74 | 56 | 57 | 56 | 16 | 13 |
| ROCE % | 15 | 15 | 16 | 15 | 12 | 10 | 3 | 7 | 10 | 9 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% | 47.68% | 47.68% | 47.68% | 47.68% | 47.68% |
| FIIs | 23.21% | 20.29% | 19.06% | 19.49% | 17.94% | 16.96% | 17.22% | 17.4% | 16.57% | 15.96% | 15.9% | 15.87% |
| DIIs | 1.65% | 1.5% | 3.78% | 4.07% | 5.66% | 6.98% | 7.05% | 9.53% | 10.52% | 11.22% | 11.62% | 12.4% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 18.24% | 18.76% | 18.71% | 17.79% | 18.09% | 18.09% | 17.75% | 17.97% | 18.02% | 17.85% | 17.57% | 17.16% |
| Others | 6.22% | 8.77% | 7.77% | 7.97% | 7.63% | 7.3% | 7.31% | 7.42% | 7.22% | 7.29% | 7.23% | 6.89% |
| No. of Shareholders | 89376 | 86588 | 92264 | 81992 | 89456 | 102442 | 96526 | 99673 | 93336 | 90133 | 86347 | 82703 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 2 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 954.01 | Buy |
| EMA (10) | 969.98 | Buy |
| SMA (20) | 917.03 | Buy |
| EMA (20) | 944.68 | Buy |
| SMA (50) | 944.43 | Buy |
| EMA (50) | 940.66 | Buy |
| SMA (100) | 959.33 | Buy |
| EMA (100) | 947.65 | Buy |
| SMA (200) | 959.66 | Buy |
| EMA (200) | 963.05 | Buy |

### Oscillators — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 74.08 | Sell |
| MACD (12,26,9) | 21.42 | Buy |
| Stochastic (14,3,3) | 96.99 | Sell |
| ADX (14) | 23.39 | Neutral |
| Williams %R (14) | -5.28 | Sell |
| ATR (14) | 31.69 | High Volatility |
| ROC (12) | 15.53 | Buy |
| Stoch RSI (14) | 99.51 | Sell |
| UO (7,14,28) | 70.85 | Sell |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 3 | 75% |
| Hold | 0 | 0% |
| Sell | 1 | 25% |

Based on 4 analyst ratings, observed at 2026-09-11T04:48:41.572862+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 8h - FY2026 earnings webinar scheduled for May 22, 2026, 6:00-7:00 pm IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8h - FY2026 earnings webinar scheduled for May 22, 2026, 6:00-7:00 pm IST.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4e417f73-16a0-446a-b7ad-caa3c0021f34.pdf) |
| 8h - Board meeting on May 22, 2026 to consider FY26 audited results and final dividend. | [Board Meeting Intimation for Meeting Held On May 22, 2026 8h - Board meeting on May 22, 2026 to consider FY26 audited results and final dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2107f772-8071-4861-a745-d0f01e23694d.pdf) |
| 6h - Earnings webinar on FY2026 financial performance scheduled for May 22, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6h - Earnings webinar on FY2026 financial performance scheduled for May 22, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/840066a3-172b-4654-afb8-bcd03daceb18.pdf) |
| 6 Feb - Q3 revenue Rs2,123Cr (+17%); Normalised PAT Rs86Cr; Montreal CDMO shut for FDA remediation, production resumed Q4. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Feb - Q3 revenue Rs2,123Cr (+17%); Normalised PAT Rs86Cr; Montreal CDMO shut for FDA remediation, production resumed Q4.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/417b2d60-93cb-41ee-894e-0fb0d9135b08.pdf) |
| 30 Mar - Notifying shareholders unpaid FY2018-19 dividend to transfer to IEPF on Oct 31, 2026; claim by May 15, 2026. | [Submission Of Communication Sent To Shareholders 30 Mar - Notifying shareholders unpaid FY2018-19 dividend to transfer to IEPF on Oct 31, 2026; claim by May 15, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0f805932-dc24-4c47-8e07-db25d6624bd5.pdf) |
| 27 Mar - Trading window closed Apr 1, 2026 until 48 hours after audited FY2026 results announcement. | [Closure of Trading Window 27 Mar - Trading window closed Apr 1, 2026 until 48 hours after audited FY2026 results announcement.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0364b04c-ee79-4a04-b222-eadd043d7212.pdf) |
| 27 Feb - Newspaper Advertisement relating to Notice of Shareholders | [Announcement under Regulation 30 (LODR)-Newspaper Publication 27 Feb - Newspaper Advertisement relating to Notice of Shareholders](https://www.bseindia.com/xml-data/corpfiling/AttachHis/622bc71a-edf0-4dd9-b354-6df51a1e5f42.pdf) |
| 24 Apr - FY2026 earnings webinar scheduled for May 22, 2026, 6:00-7:00 pm IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Apr - FY2026 earnings webinar scheduled for May 22, 2026, 6:00-7:00 pm IST.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4e417f73-16a0-446a-b7ad-caa3c0021f34.pdf) |
| 24 Apr - Earnings webinar on FY2026 financial performance scheduled for May 22, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Apr - Earnings webinar on FY2026 financial performance scheduled for May 22, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/840066a3-172b-4654-afb8-bcd03daceb18.pdf) |
| 24 Apr - Board meeting on May 22, 2026 to consider FY26 audited results and final dividend. | [Board Meeting Intimation for Meeting Held On May 22, 2026 24 Apr - Board meeting on May 22, 2026 to consider FY26 audited results and final dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2107f772-8071-4861-a745-d0f01e23694d.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-01 | [Receipt Of Show Cause Notice By Jubilant Pharmova Limited - GST](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ca731a5-bb79-467b-b2c4-44e3919f2646.pdf) |
| 2026-08-29 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9c861cc3-918a-421c-bd54-2e3f49b70a00.pdf) |
| 2026-08-28 | [Receipt Of Show Cause Notice - Jubilant Generics Limited](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f0d3c070-e36e-4b7d-bcfc-63c3e64172e0.pdf) |
| 2026-08-26 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b2fe326-9496-47fd-81f2-4dfccc16c3a7.pdf) |
| 2026-08-26 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a111850-da99-463c-b556-3cf9139cd500.pdf) |
| 2026-08-23 | [USFDA Approval For Line 3 Contract Manufacturing Facility Spokane U.S.A](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e014f41-46f0-4b3d-bd91-9c59fd8b5207.pdf) |
| 2026-08-17 | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=efc777ff-4611-4b24-999a-59c2a80a0f41.pdf) |
| 2026-08-17 | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=492802e2-8cda-4e51-8ac8-9ee16e331d0f.pdf) |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b950b041-3a72-47f2-ab61-5ce7b3c03d54.pdf) |
| 2026-08-10 | [Board Meeting Outcome for Meeting Held On August 10 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23b1daa6-d33f-49bf-a692-f57b1fe2fe3c.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-10 | [Un-Audited Standalone & Consolidated Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eae8054d-5f97-41e5-9d6b-6d870ffbb885.pdf) |
| 2026-05-22 | [Audited Financial Results For The Quarter And Year Ended March 31. 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17d96331-cd92-4b5f-ab4e-ea646ad0290b.pdf) |
| 2026-02-06 | [Un-Audited Financial Results For Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bdbc421-668d-46c2-98ea-e564221bea21.pdf) |
| 2025-10-31 | [Un-Audited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c54bdc76-b062-4253-8a6d-80c4f1d41d3d.pdf) |
| 2025-07-29 | [Unaudited Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2dde98ab-c362-4633-b127-e34d36eade54.pdf) |
| 2025-05-16 | [Audited Results For The Quarter And Financial Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=94172736-4639-436f-a19c-8c3a94055f96.pdf) |
| 2025-01-31 | [Unaudited Results For The Quarter Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d6a4e2f-6c02-48a1-9492-dabeb981a51c.pdf) |
| 2024-10-25 | [Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=349bf8a8-cce9-4870-8269-d95e5b6ae20c.pdf) |
| 2024-07-19 | [Unaudited Financial Results For June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4c50068-6906-4d8f-ad3a-e2b56af0ee83.pdf) |
| 2024-05-29 | [Audited Financial Results For March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6c39d01-03ae-487e-937d-12457fd8e683.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2025 | [Concall - Oct 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77615ab8-04a3-4a72-9b9e-3d3fe8271bc1.pdf) |
| Oct 2025 | [Concall - Oct 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/77615ab8-04a3-4a72-9b9e-3d3fe8271bc1.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa20914b-5d6b-462a-962f-9c48604d50ba.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/aa20914b-5d6b-462a-962f-9c48604d50ba.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c179b6ae-2eca-4b92-9862-0b531944d11f.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c179b6ae-2eca-4b92-9862-0b531944d11f.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b397ac5-8f56-49ed-839c-0ac0a12aa336.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8b397ac5-8f56-49ed-839c-0ac0a12aa336.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/71a29434-2d98-42bc-81c9-221b412a83a7.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/71a29434-2d98-42bc-81c9-221b412a83a7.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/73662119-bff3-405b-9a4e-a40436f94478.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/519f6679-b13e-4ebc-8902-43ae69dd36a2.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/17acce2d-361c-4ca3-bdad-ef45d680aa62.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ce32bed6-c010-4f8f-a1d4-04318b1b6874.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/530019/75805530019.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/530019/70208530019.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/530019/5300190320.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/530019/5300190319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/530019/5300190318.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2025-02-24 | [Audio Recording Of Investors / Analysts Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8492a875-a254-45c1-8dbf-97bb22cc4ebc.pdf) |
| 2023-02-03 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=294a6d26-e84f-4078-b805-3e676432b857.pdf) |
| 2022-10-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f7210d1-9888-4194-9b37-9da6c2cb0e85.pdf) |
| 2022-05-28 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ad98d7d-e15c-4e03-a9be-9ef39475a442.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2023-02-09 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=016b00cc-23e6-4946-ba9c-6e3ddbd9307c.pdf) |
| 2022-08-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0757cee2-24f0-46c9-8e00-5c5e7bdbfbe3.pdf) |
| 2022-08-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=51eae07f-e035-48d9-8fa3-668183ef20fc.pdf) |
| 2022-06-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=478e6514-da3f-4034-8021-636441ae5227.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2021-06-18 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=885976f9-369e-4db2-a565-7df37d10f00b.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:50:50.530Z.